Modelling the cost-effectiveness of nevirapine triple combination therapy and dual combination therapy for the treatment of HIV disease in the United Kingdom

Journal of Medical Economics

Volumn 2, Issue 1-4, 1999, Pages 85-105

  Biddle, A K ^a   Simpson, K N ^b  

^a IL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

combination therapy; cost effectiveness analysis; HIV disease

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; NEVIRAPINE; ZIDOVUDINE;

ARTICLE; BUDGET; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; STATISTICAL MODEL; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0033360842     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/199902085105     Document Type: Article

References (45)

1. Ioaniddis J P H, Sacks HS, Cappelleri JC et al. Clinical efficacy of antiretroviral therapies in treatment-experienced HIV-infected patients: A meta-analysis. Online J Curr Clin Trials (serial online), 15 May 1997, Document # 204.
2. Coffin JM. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis and therapy. Science 1995;267:483-9.
3. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from fidelity of purified reverse transcriptase. J Virol 1995;69:5987-94.
4. Moyle GJ. Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences. Drugs 1996;52:168-85. (Pubitemid 26258458)
5. Gazzard B, Moyle G on behalf of the BHIVA Guidelines Writing Committee. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998;352:314-6. (Pubitemid 28340161)
6. Carpenter C C J, Fischl MA, Hammer SM et al Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society-USA Panel. JAMA 1998;280:78-86. (Pubitemid 28415001)
7. Beck EJ, Tolley K, Power A et al. The use and cost of HIV service provision in England in 1996. Pharmaco Economics 1998;14:639-52. (Pubitemid 29006167)
8. D'Aquila RT, Hughes MD, Johnson VA et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124:1019-30.
9. Montaner J, Reiss P, Cooper D et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA 1998;279:930-7. (Pubitemid 28136082)
10. Montaner J, Reiss P, Cooper D et al. Longterm follow-up of patients treated with nevirapine (NVP) based combination therapy within the INCAS trial. Abstract 695. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 1-5 February 1998.
11. Petrou S, Dooley M, Whitaker L et al. The economic costs of caring for people with HIV infection and AIDS in England and Wales. Pharmaco Economics 1996;9:332-40.
12. Schulman KA, Lynn LA, Glick HA et al. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 1991;114:798-802.
13. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection. Pharmaco Economics 1996;10:109-13. (Pubitemid 26281111)
14. Simpson K, Andersson F, Shakespeare A et al. Cost effectiveness of antiretroviral treatment with zalcitabine in combination with zidovudine for AIDS patients with CD4 counts < 300 per mm in five European countries. PharmacoEconomics 1994;6:553-62.
15. Mauskopf J, Simpson K. The costs and benefits of alternative drug treatment regimens for HIV patients. 3rd Conference on Retroviruses and Opportunistic Infections, Infectious Disease Society of America, Washington, DC, 30 January 1996.
16. Simpson KN, LaVallee RL. Combination therapy in eight developed countries: Events and costs of therapy with saquinavir, zalcitabine, and zidovudine therapy in Australia, Canada, Germany, Italy, Spain, Switzerland, UK, and USA. 3rd International Congress on Drug Therapy in HIV Infections, Birmingham, United Kingdom, 5 November 1996.
17. Chancellor JV, Hill AM, Sabin CA et al. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy for HIV infection. Pharmaco Economics 1997;12:1-13.
18. Anis AH, Hogg RS, Wand X-H et al. Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy. Pharmaco Economics 1998;13:697-705. (Pubitemid 28247661)
19. 3. Multicenter AIDS Cohort Study. J Infect Dis 1994;170:1280-7.
20. Colford JM Jr. Ngo L, Tager I. Factors associated with survival in human immunodeficiency virus-infected patients with very low CD4 counts. Am J Epidemiol 1995;141:788-9.
21. Selvin S. Statistical Analysis of Epidemiological Data. New York: Oxford University Press, 1996:33.
22. Boehringer Ingelheim Ltd, United Kingdom, 27 February 1998. Price unchanged since launch and now published in Monthly Index of Medical Specialities (MIMS), March 1999.
23. Cameron DW, Japour A, Mellors JW et al. Antiretroviral safety & durability of ritonavir (RIT)-saquinavir (SAQ) in protease inhibitor-naïve patients in year two followup. Abstract 388. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 1-5 February 1998.
24. Hirsch EM, Meibohm A, Rawlins S et al. Indinavir (IDV) in combination with ZDV and 3TC in ZDV-experienced patients with CD4 cell count <50 cells/mm. Abstract 383. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 1-5 February 1998.
25. Markowitz M, Cao Y, Hurley A et al. Virologic and immunologic response to triple therapy with nelfinavir in combination with AZT/3TC in 12 antiretroviral naïve HIV infected subjects at 10 months. Abstract 371. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 1-5 February 1998.
26. Gulick RM, Mellors JW, Halvir D et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection. JAMA 1998;280:35-41. (Pubitemid 28414994)
27. Cassano P, Hermans P, Sommereijns B et al. Combined quadruple therapy with ritonavir-saquinavir (RTV-SQV) + nucleosides in patients who failed in triple therapy with RTV, SQV or indinavir (IDV). Abstract 423. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 1-5 February 1998.
28. Gallant JE, Hall C, Barnett S et al. Ritonavir/saquinavir (RTV/SQV) as salvage therapy after failure of initial protease inhibitor (PI) regimen. Abstract 427. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 1-5 February 1998.
29. Lawrence J, Schapiro J, Winters M et al. Salvage therapy with indinavir plus nevirapine in patients previously treated with two other protease inhibitors and multiple reverse transcriptase inhibitors. Abstract 422. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 1-5 February 1998.
30. Mayers DL, Neaton JD, Perez G et al. Prior saquinavir therapy leads to a models decrease in subsequent responses to drug regimens containing indinavir or ritonavir. Abstract 400. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 1-5 February 1998.
31. Tebas P, Kane E, Klebert M et al. Virologic responses to ritonavir/saquinavir containing regimen in patients who have previously failed Nelfinavir. Abstract 510. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 1-5 February 1998.
32. Laurence J. HAART regimens: Do the effects last? A report from Toronto. AIDS Reader, Medscape (http://www.medscape.com).
33. Petrou S, Dooley M, Whitaker L et al. Cost and utilisation of community health services for people with HIV infection in London. Health Trend 1995;27(2):62-8.
34. NHS Executive. Hospital Community Health Services Index (HCHS). Leeds: NHS Executive, April 1999.
35. Staszewski S, Hill AM, Bartlett J et al. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: A meta-analysis of controlled trials. AIDS 1997;11:477-83. (Pubitemid 27113009)
36. Condra JH, Schlief WA, Blahy OM et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
37. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: A review for clinicians. JAMA 1997;277:145-53. (Pubitemid 27030184)
38. Johannesson M. On the discounting of gained life-years in cost-effectiveness analysis. Int J Technol Assess Health Care. 1992;8(2):359-64.
39. Lipscomb J, Weinstein MC, Torrance GW. Time Preference. In Gold MR, Siegel JE, Russell LB et al (eds.) Cost-Effectiveness in Health and Medicine. 1996. New York: Oxford University Press: 214-46.
40. The Joint Government/Pharmaceutical Industry Working Party. UK guidance on good practice in the conduct of economic evaluations of medicines. Br J Med Econ 1994;7:63-4.
41. United States Federal Reserve Board. International Statistics. 3.28 Foreign Exchange Rates. Federal Reserve Bulletin. 1998;84(4):A62.
42. Moore RD, Hidalgo J, Bareta JC et al. Zidovudine therapy and health resources utilization in AIDS. J Acquired Immune Defic Syndrome 1994;7:349-54. (Pubitemid 24100839)
43. Laupacis A, Feeny D, Detsky AS et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Assoc J 1992;146:473-81.
44. Kaspar R, Werntz G, DuBois DB. Early results of combined stavudine, lamivudine, and nevirapine: A twice daily, well tolerated protease inhibitor-sparing regimen for the treatment of HIV-1 infection. Abstract 669. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 1-5 February 1998.
45. Rieger A, Hein U, Schon H et al. Nevirapine+ddI+3TC-First experience with a once-daily dosing combination regimen. Abstract 697. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, February 1-5, 1998.